Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMC-DRIP desensitization study in highly sensitized kidney transplant candidates
NL-OMON26482Not yet recruiting
- Sponsor
- Dr. Ajda T. Rowshani; Nephrologist-Clinical Immunologist Academic Medical Center Department of Internal Medicine, F4-215 PO Box 22700 100 DE Amsterdam, The Netherlands Tel: +31-20-5663365 page 58816 Fax: +31-20-6914904 E-mail:[email protected]
- Start
- Jul 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of rituximab and Nanogam in end-stage kidney disease (ESKD), sponsored by Dr. Ajda T. Rowshani; Nephrologist-Clinical Immunologist Academic Medical Center Department of Internal Medicine, F4-215 PO Box 22700 100 DE Amsterdam, The Netherlands Tel: +31-20-5663365 page 58816 Fax: +31-20-6914904 E-mail:[email protected]. Primary endpoint: Achievement of negative cross-match and transplantability. Planned start Jul 2007; status: not yet recruiting.
02
Drugs
rituximabNanogam
03
Conditions
end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on NL-OMON26482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON26482.